Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2013007419
pages 435-467

A Pharmacokinetic Overview of Nanotechnology-Based Drug Delivery Systems: An ADME-Oriented Approach

Mehrdad Hamidi
Department of Pharmaceutics, School of Pharmacy, Zanjan University of Medical Science
Amir Azadi
Shiraz University of Medical Sciences
Pedram Rafiei
College of Pharmacy and Nutrition, University of Saskatchewan, Canada
Hajar Ashrafi
Department of Pharmaceutics, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran


With the extensive progress in nanotechnology-based drug delivery systems, pharmacokinetic evaluations have gained much attention from researchers as a central part of the study of these systems. Because the fulfillment of any therapeutic goal(s) by a novel drug delivery system requires that the absorption, distribution, metabolism, and excretion (ADME) be considered from the early stages of the system design to the final clinical evaluations, extensive knowledge of the pharmacokinetic aspects related to ADME is a crucial part of research in this field. The main objectives of the nanotechnology-based drug delivery systems from a pharmacokinetic viewpoint are (1) an improved drug-release profile in vivo, (2) enhanced drug absorption, (3) site-directed drug distribution, (4) a modified drug metabolism pattern, (5) prolonged drug residence time in body (e.g., in blood circulation), and (6) delayed and/or decreased renal excretion of the drug. Accordingly, the purpose of the current review is to present an insightful summary of pharmacokinetic analyses of nanotechnology-based drug delivery systems along with a critical review of recent findings.

Articles with similar content:

Remote Controlled Capsules in Human Drug Absorption (HDA) Studies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 6
David V. Prior, Ian R. Wilding
Controlled-Release Products for the Control of the Estrus Cycle in Cattle, Sheep, Goats, Deer, Pigs, and Horses
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.15, 1998, issue 4
Michael J. Rathbone, E. Keith Inskeep, Maurice P. Boland, Wolfgang Jochle, Keith L Macmillan
Gastroretentive Floating Drug-Delivery Systems: A Critical Review
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 1
Moji Christianah Adeyeye, Udaya Kotreka
Pulmonary Drug Delivery: Physiologic and Mechanistic Aspects
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.14, 1997, issue 4
Jianwei Yu, Yie W. Chien
Optimizing Drug Delivery Systems Using Systematic "Design of Experiments." Part II: Retrospect and Prospects
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.22, 2005, issue 3
Naveen Ahuja, Vandana Saharan, Bhupinder Singh, Manju Dahiya